Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Aducanumab

Amyloid rebound in Alzheimer's disease: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Patel S, et al. Treatment interval dependent effects of aducanumab therapy on Alzheimer's disease neuropathology. Journal of Neuropathology and Experimental Neurology 82 : 489-490, No. 6, Jun 2023. Available from: URL: http://doi.org/10.1093/jnen/nlad029 [abstract] Patel S, et al. Treatment interval dependent effects of aducanumab therapy on Alzheimer's disease neuropathology. Journal of Neuropathology and Experimental Neurology 82 : 489-490, No. 6, Jun 2023. Available from: URL: http://​doi.​org/​10.​1093/​jnen/​nlad029 [abstract]
Metadaten
Titel
Aducanumab
Amyloid rebound in Alzheimer's disease: 2 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43474-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Iodixanol

Case report

Multiple drugs

Case report

Paclitaxel

Case report

Various drugs

Case report

Valganciclovir